Laidlaw & Co. Initiates Coverage On SILO Pharma with Buy Rating, Announces Price Target of $10
Portfolio Pulse from richadhand@benzinga.com
Laidlaw & Co. has initiated coverage on SILO Pharma (NASDAQ:SILO) with a Buy rating and a price target of $10.
August 28, 2023 | 8:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SILO Pharma has been given a Buy rating by Laidlaw & Co. with a price target of $10.
The Buy rating and price target of $10 announced by Laidlaw & Co. for SILO Pharma indicates a positive outlook for the company. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100